A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
Adult T-cell Leukemia, Lymphoma
About this trial
This is an interventional treatment trial for Adult T-cell Leukemia focused on measuring ATLL, chemotherapy, phase III study, VCAP-AMP-VECP, biweekly-CHOP
Eligibility Criteria
Inclusion Criteria: Diagnosis of ATL was made based on seropositivity for HTLV-I by either enzyme-linked immunosorbent assay or particle agglutination assay, and histologically- and/or cytologically-proven peripheral T-cell malignancy Aggressive ATL, i.e., acute-, lymphoma- or unfavorable chronic-type ATL Aged 15-69 years No prior chemotherapy or radiotherapy Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 or 4 as a result of hypercalcemia Preserved organ (bone marrow, liver, kidney, heart and lung) functions All patients were required to provide written informed consent Exclusion Criteria: Diabetes mellitus necessitating treatment with insulin Active systemic infection Cardiac disorders expected to become worse as a result of the DOX-containing regimen Acute hepatitis, chronic hepatitis or liver cirrhosis Positive for HBs Ag or anti-HCV Ab Active concurrent malignancy Other serious medical or psychiatric conditions Pregnancy or breast feeding Central nervous system involvement by ATL cells
Sites / Locations
- Nagasaki University Graduate School of Biomedical Science